FDA.reportPublic FDA data

DEFEROXAMINE MESYLATE

Substance profile for UNII V9TKO7EO6K, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Chemical structure for DEFEROXAMINE MESYLATE
Structure render from PubChem CID 62881

Substance Identity#

UNII
V9TKO7EO6K
Preferred term
DEFEROXAMINE MESYLATE
Registry number
138-14-7
EC number
205-314-3
Ingredient type
INGREDIENT SUBSTANCE
Molecular formula
C25H48N6O8.CH4O3S
Chemical structure for DEFEROXAMINE MESYLATE
Structure render from PubChem CID 62881

Chemical And Database Identifiers#

InChIKey
IDDIJAWJANBQLJ-UHFFFAOYSA-N
SMILES
CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
RxCUI
3132
PubChem
62881
NCIt
C417
INN ID
0

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
PubChem Compound62881https://pubchem.ncbi.nlm.nih.gov/compound/62881
PubChem InChIKey SearchIDDIJAWJANBQLJ-UHFFFAOYSA-Nhttps://pubchem.ncbi.nlm.nih.gov/#query=IDDIJAWJANBQLJ-UHFFFAOYSA-N
RxNorm3132https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=3132
NCI ThesaurusC417https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C417
FDA Substance Registration SystemV9TKO7EO6Khttps://precision.fda.gov/uniisearch/srs/unii/V9TKO7EO6K
European Community number205-314-3https://commonchemistry.cas.org/results?q=205-314-3

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
DEFEROXAMINE MESYLATEACTIVE INGREDIENTV9TKO7EO6KDEFEROXAMINE MESYLATE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [HOSPIRA, INC.]11
DEFEROXAMINE MESYLATEACTIVE INGREDIENTV9TKO7EO6KDEFEROXAMINE MESYLATE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [HOSPIRA, INC.]11
DEFEROXAMINE MESYLATEACTIVE INGREDIENTV9TKO7EO6KDESFERAL (DEFEROXAMINE MESYLATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]7
DEFEROXAMINE MESYLATEACTIVE INGREDIENTV9TKO7EO6KDEFEROXAMINE (DEFEROXAMINE MESYLATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [APP PHARMACEUTICALS, LLC]4